成人KMT2A相关急性髓系白血病的临床特征与预后分析
该研究回顾性分析303例成人KMT2A相关AML患者,中位年龄41岁,KMT2Ar占81.8%、KMT2A-PTD占18.2%。KMT2A::AFDN亚型预后不良,KMT2A::MLLT3伴EVI1过表达复发风险显著升高;CR(1)移植改善预后;KMT2A-PTD对传统强化疗反应不佳,维奈克拉方案显著改善预后。
要点
- KMT2A::AFDN亚型2年CIR最高达68.5%,为不良预后因素
- KMT2A::MLLT3伴EVI1过表达者2年CIR显著高于不伴者
- KMT2A-PTD患者维奈克拉方案CR率86.7%,显著优于非靶向治疗
核心结论
- KMT2Ar AML中KMT2A::AFDN亚型预后不良,伴EVI1过表达显著增加KMT2A::MLLT3患者复发风险。
- CR(1)移植仍是改善预后的首选策略。
- KMT2A-PTD对传统强化疗反应不佳,经维奈克拉靶向治疗预后显著改善。
研究设计与样本
- 回顾性分析2014年1月至2024年8月苏州大学附属第一医院303例成人KMT2A相关AML患者临床资料。
- 分析不同伴侣基因亚组的临床生物学特征及预后差异。
主要发现
- 303例中位年龄41(16~82)岁,KMT2Ar占81.8%(248/303),KMT2A-PTD占18.2%(55/303)。
- KMT2Ar患者1个疗程CR率65.3%(162/248),2年OS率52.6%(95%CI:46.3%~59.7%),2年CIR 55.4%(95%CI:44.8%~61.6%)。
- KMT2A::AFDN亚型(69例)2年CIR最高为68.5%(95%CI:55.4%~78.5%),不常见KMT2Ar亚型(31例)最低为43.2%(95%CI:24.8%~60.3%)。
- KMT2A::MLLT3伴EVI1过表达者(18例)2年CIR 66.7%(95%CI:38.5%~84.2%),高于不伴者(53例)的44.0%(95%CI:30.1%~57.0%)(P=0.018)。
关键数值与推荐
- KMT2A-PTD患者1个疗程CR率60.0%(33/55);维奈克拉方案与非靶向方案CR率分别为86.7%(26/30)和28.0%(7/25)(P<0.001)。
- KMT2A-PTD维奈克拉方案与非靶向方案2年OS率分别为68.7%(95%CI:36.1%~87.1%)和53.9%(95%CI:32.2%~71.4%)(P=0.035),2年CIR分别为34.2%(95%CI:15.9%~53.5%)和78.7%(95%CI:54.2%~91.0%)(P=0.002)。
- KMT2A-PTD强化疗与减低强度化疗CR率分别为40.7%(11/27)和78.6%(22/28)(P=0.004),2年CIR分别为72.3%(95%CI:47.6%~86.8%)和41.7%(95%CI:20.6%~61.6%)(P=0.017)。
- CR(1)移植(156例)与非CR(1)移植(62例)2年OS率分别为74.1%(95%CI:66.9%~82.0%)和52.0%(95%CI:40.6%~66.7%),2年CIR分别为27.3%(95%CI:20.0%~34.9%)和91.9%(95%CI:80.8%~96.7%)(均P<0.001)。
- Cox多因素分析:1个疗程达CR(OS:HR=0.54,P<0.001;CIR:HR=0.67,P=0.010)及allo-HSCT(OS:HR=0.17,P<0.001;CIR:HR=0.41,P<0.001)为有利因素;KMT2A::AFDN为OS(HR=1.51,P=0.029)和CIR(HR=1.56,P=0.006)的危险因素。
临床怎么用
- 对KMT2Ar AML应识别伴侣基因亚型,KMT2A::AFDN提示不良预后。
- KMT2A::MLLT3患者应评估EVI1过表达以识别高复发风险。
- KMT2A-PTD患者优先考虑维奈克拉为基础的靶向治疗而非传统强化疗。
- 获得CR(1)后应尽早行异基因造血干细胞移植以改善预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the clinicobiological characteristics and prognostic impact of different fusion partners of KMT2A in acute myeloid leukemia (AML) . Methods: The clinical features of 303 patients with KMT2A-associated AML who received treatment between January 2014 and August 2024 were retrospectively analyzed to investigate prognostic differences among fusion partner subgroups. Results: Among 303 patients with KMT2A-associated AML, the median age was 41 (16-82) years. KMT2A-PTD accounted for 18.2% (55/303), whereas KMT2A rearrangements (KMT2Ar) were observed in 81.8% (248/303). Among KMT2Ar AML patients, the complete remission (CR) rate after a course of induction treatment was 65.3% (162/248), whereas the 2-year overall survival (OS) rate and cumulative incidence of relapse (CIR) were 52.6% (95% CI: 46.3% -59.7% ) and 55.4% (95% CI: 44.8% -61.6% ), respectively. Prognoses varied across partner gene subtypes; the KMT2A::AFDN subgroup (n=69) had the poorest 2-year CIR of 68.5% (95% CI: 55.4% -78.5% ), whereas the uncommon KMT2Ar subgroup (n=31) had a 2-year CIR rate of 43.2% (95% CI: 24.8% -60.3% ). The group with KMT2A::MLLT3 and EVI1 overexpression (n=18) exhibited a significantly higher 2-year CIR, at 66.7% (95% CI: 38.5% -84.2% ) versus 44.0% (95% CI: 30.1% -57.0% ) for those with KMT2A::MLLT3 who did not show EVI1 overexpression (n=53) (P=0.018). Among patients with KMT2A-PTD, the CR rate after a course of treatment was 60.0% (33/55) ; venetoclax-based therapy yielded a significantly higher CR rate compared with nontargeted therapy: 86.7% (26/30) vs 28.0% (7/25) (P<0.001), with a 2-year OS rate of 68.7% (95% CI: 36.1% -87.1% ) versus 53.9% (95% CI: 32.2% -71.4% ) (P=0.035), and 2-year CIR rate of 34.2% (95% CI: 15.9% -53.5% ) versus 78.7% (95% CI: 54.2% -91.0% ) (P=0.002). Compared to low-intensity chemotherapy, intensive chemotherapy resulted in a significantly lower CR rate: 40.7% (11/27) versus 78.6% (22/28) (P=0.004), accompanied by a higher 2-year CIR[72.3% (95% CI: 47.6% -86.8% ) versus 41.7% (95% CI: 20.6% -61.6% ), P=0.017]. Among transplant patients, those undergoing hematopoietic stem cell transplantation (HSCT) in CR1 (n=156) had better outcomes than those transplanted in non-CR1 (n=62), with a 2-year OS rate of 74.1% (95% CI: 66.9% -82.0% ) versus 52.0% (95% CI: 40.6% -66.7% ) and 2-year CIR of 27.3% (95% CI: 20.0% -34.9% ) versus 91.9% (95% CI: 80.8% -96.7% ), respectively (both P<0.001). Multivariate Cox regression analysis showed that achieving CR after one induction cycle (HR=0.54, P<0.001; HR=0.67, P=0.010) and receiving allo-HSCT (HR=0.17, P<0.001; HR=0.41, P<0.001) were favorable prognostic factors for OS and CIR. KMT2A::AFDN was an adverse prognostic factor for both OS (HR=1.51, P=0.029) and CIR (HR=1.56, P=0.006) . Conclusion: In KMT2Ar AML, the KMT2A::AFDN subtype was associated with adverse prognosis, whereas concomitant EVI1 overexpression significantly increased the risk of relapse in KMT2A::MLLT3 subgroup. allo-HSCT in CR(1) significantly improves prognosis in these patients. The KMT2A-PTD group showed poor response to conventional intensive chemotherapy but achieved significantly improved prognosis with venetoclax-based therapy. 目的: 探讨成人KMT2A相关急性髓系白血病(AML)的临床生物学特征及不同亚型对预后的影响。 方法: 回顾性分析2014年1月至2024年8月期间于苏州大学附属第一医院就诊的303例成人KMT2A相关AML患者临床资料,分析不同伴侣基因亚组的临床生物学特征及预后差异。 结果: 303例KMT2A相关AML患者,中位年龄41(16~82)岁。KMT2A重排(KMT2Ar)AML占81.8%,KMT2A部分串联重复(KMT2A-PTD) AML占18.2%。KMT2Ar AML患者1个疗程完全缓解(CR)率为65.3%(162/248),2年总生存(OS)率及累积复发率(CIR)分别为52.6%(95%CI:46.3%~59.7%)、55.4%(95%CI:44.8%~61.6%)。各伴侣基因亚型CIR存在差异,KMT2A::AFDN亚型(69例)2年CIR最高,为68.5%(95%CI:55.4%~78.5%);不常见KMT2Ar亚型(31例)2年CIR率最低,为43.2% (95%CI:24.8%~ 60.3%)。伴EVI1过表达的KMT2A::MLLT3患者(18例)2年CIR为66.7%(95%CI:38.5%~84.2%),较不伴EVI1过表达的KMT2A::MLLT3患者(53例)的44.0%(95%CI:30.1%~57.0%)显著升高(P=0.018)。KMT2A-PTD患者中,1个疗程CR率为60.0%(33/55);维奈克拉靶向治疗和非靶向治疗患者CR率分别为86.7%(26/30)和28.0%(7/25)(P<0.001),2年OS率分别为68.7%(95%CI:36.1%~87.1%)和53.9%(95%CI:32.2%~71.4%)(P=0.035),2年CIR分别为34.2% (95%CI:15.9%~53.5%)和78.7% (95%CI:54.2%~91.0%)(P=0.002);强化疗和减低强度化疗患者CR率分别为40.7%(11/27)和78.6%(22/28)(P=0.004),2年CIR分别为72.3% (95%CI:47.6%~86.8%)和41.7% (95%CI:20.6%~61.6%)(P=0.017)。移植患者中,首次CR(CR(1))移植(156例)和非CR(1)移植患者(62例)2年OS率分别为74.1%(95%CI:66.9%~82.0%)和52.0%(95%CI:40.6%~66.7%),2年CIR分别为27.3%(95%CI:20.2%~34.9%)和91.9%(95%CI:80.8%~96.7%)(均P<0.001)。Cox多因素分析示1个疗程达CR(P<0.001,HR=0.54;P=0.010,HR=0.67)及异基因造血干细胞移植(P<0.001,HR=0.17;P<0.001,HR=0.41)是影响OS和CIR的有利因素,KMT2A::AFDN是影响OS(P=0.029,HR=1.51)和CIR(P=0.006,HR=1.56)的危险因素。 结论: KMT2Ar AML中,KMT2A::AFDN亚型预后不良,伴EVI1过表达显著增加KMT2A::MLLT3患者复发风险;CR(1)移植仍是改善预后的首选策略。KMT2A-PTD对传统强化疗反应不佳,经维奈克拉靶向治疗预后显著改善。.
引用
- Zhou XY, Wei XE, Liu Y, et al. [Clinical characteristics and prognostic analysis of adult KMT2A-associated acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42161656. doi:10.3760/cma.j.cn121090-20250526-00247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。